Coenzyme Q10

Producers shown on SFDA

(Record date:31/08/2021）

Producers shown on EP

Not showing any

Producer:Founded in 1999，Zhejiang NHU Co., Ltd. was listed on Shenzhen Stock Exchange in 2004 as the first stock of SME board (code: 002001). The company has total assets of 21.9 billion yuan and has four modern production bases in Xinchang, Shangyu, Weifang and Suihua.

The company's leading products are ve, VA, VH, VD3 and carotenoids, with a market share in the forefront of th world. Relying on continuous technological progress, improving quality and reducing cost, relying on global marketing network and good service, the company has become one of the most important vitamin manufacturers in the world.

Staff size:About 10000 persons

Registered capital:RMB 2 billion 578 million

Producer:Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997.After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market. In October, the company's shares were then listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 980 million yuan in registered capital and total assets of 10 billion yuan.

The company has first-class chemical pharmaceutical, microbial pharmaceutical and preparation production facilities that meet GMP requirements, and also produces natural drugs, food additives and feed additives. It is an important production base of vitamins, antibiotics and fluoroquinolones in China. The leading products are synthetic vitamin E, accounting for 25% of the global output; Natural vitamin E is the largest producer in China and the third largest producer in the world; Biotin accounts for more than 60% of the global output; Levofloxacin lactate injection (lailixin), accounting for 20% of the country; Coenzyme Q10 accounts for 20% of the world; Vancomycin hydrochloride accounts for 30% of the world; Teicoplanin accounts for 100% of the country and 30% of the world.

Staff size:About 3000 persons

Registered capital:RMB 980 million

Producer:Yuxi Jiankun Bio-Pharmaceutical Co., Ltd. has a precision chartered workshop meeting the 100000 GMP standard, and obtained the production license of coenzyme Q10 API issued by the State Drug Administration in October 2005. The product quality fully meets the technical indexes required by the Chinese Pharmacopoeia 2005 edition and the US pharmacopoeia 28 edition. The company also produces high-purity solanesol, royal jelly acid and solanesylamine. Yuxi is one of the largest tobacco planting bases in the world, with rich resources for the production of coenzyme Q10. In addition to our own crude solanesol plants, our company also has four crude solanesol plants in the surrounding areas, which provide a stable supply of goods for a long time and ensure the stable and balanced output of coenzyme Q10. The company has reached the production scale of 1000kg per month by the end of 2005, and will complete the production scale of 3000kg per month in 2006.

Staff size:About 50 persons

Registered capital:RMB 16 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978